Poly Medicure Limited announced that its Board of Directors approved a final dividend of Rs 3.50 per equity share during the meeting held on May 25, 2026. The recommendation covers 70% of the Rs 5 face value of shares for the financial year 2025-26. This decision follows the board's review of the company's financial performance for the period ending March 31, 2026.
The dividend proposal is subject to shareholder approval as mandated by regulatory requirements. The company has not specified a timeline for the shareholder voting process or any related procedures. Poly Medicure Limited will communicate further details regarding the approval process through official channels.
This dividend recommendation aligns with the company's financial position as reflected in its audited results for the year ended March 31, 2026. The board's decision confidence in the company's operational stability and cash flow generation capabilities. No specific financial metrics or ratios were disclosed in the filing to support the dividend announcement.
Poly Medicure Limited's regulatory filing emphasizes compliance with SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations. The board's action adheres to procedural guidelines under Regulation 30 and 33 of the SEBI LODR framework. The company has not provided additional context about its dividend policy or historical payout patterns in the filing.
The announcement does not include details about the company's future dividend plans or any changes to its capital structure. Investors are advised to monitor official communications from the company for updates on shareholder approval timelines and related corporate actions. The dividend recommendation represents a material corporate action requiring shareholder engagement.
Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.